Skip to content
Company Analysis

West Pharmaceutical Services, I WST

A comprehensive view of key metrics, scores, and financial health for West Pharmaceutical Services, I

Overview of West Pharmaceutical Services, Inc.

WST NYQ
Healthcare Medical Instruments & Supplies Large Cap
West Pharmaceutical Services, Inc. (WST), is a Large Cap company, in the Medical Instruments & Supplies industry, last closed at $235.46, about 60.6% overvalued vs fair value, +1.7% 1Y return, placing in the top 25% of its sector.
$235.46
1.89%
As of March 13, 2026
Previous close • Vol 90d: 34.1%
52-Week Range
Market Cap
$17.71B
Enterprise Value
$17.24B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for West Pharmaceutical Services, I.

Top Beats

Quick Facts

Website https://www.westpharma.com
HQ Exton, PA
Employees 10,800
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$83
$93
$103
Current: $235.46 -61% vs base

Engine Room Money Flow™

Large Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$3.1B
6.2%%
Gross Profit
$1.1B
10.5%%
Operating Income
$617.4M
4.5%%
Net Income
$493.7M
0.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
56.0%
Fair

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$222.8M
80.6% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
1/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating West Pharmaceutical Services, I's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
73
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
65
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing WST's balance between Growth (24.7%), Profitability (42.2%), and Safety (33.1%). Growth 25% Safety 33% Profitability 42%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

47th percentile vs peers
48
Key Signals
Rev Growth YoY 6.2% 60p Revenue CAGR 3Y 2.1% 40p EPS Growth YoY -15.2% 38p TSR -15.7% 65p EPS CAGR 3Y -8.3% 35p
Strengths
  • Interest Coverage Ratio in top 20% of peers (998.67, 98th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Roic in top 20% of peers (16.8%, 92th percentile)
Risks

No significant risks identified for this axis.

Profitability

81th percentile vs peers
81
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

63th percentile vs peers
64
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for West Pharmaceutical Services, I.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$92.67
- - -
-60.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info